Clinical trial · Observational
Real-world Study of UTD1 in Chinese Advanced Breast Cancer
An Observational, Real-world Study Study of UTD1 in Chinese Advanced Breast Cancer
NCT05386511CI-TRIAL-00074362completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To evaluate the efficacy and safety of UTD1 in patients with advanced breast cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (1)
- label
- UTD1
- description
- UTD1 monotherapy or UTD1 based therapy
Primary outcomes (1)
- measure
- PFS
- timeFrame
- 6 weeks
- description
- Progression free survival
Secondary outcomes (1)
- measure
- Adverse events
- timeFrame
- 6 weeks
- description
- Number of participants with treatment-related adverse events as assessed by CTCAE v 5.0
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Patients aged over 18 years old. 2. Metastatic breast cancer included unresectable locally advanced breast cancer, de novo stage IV breast cancer, and recurrent metastatic breast cancer. 3. Plan to receive or has received UTD1 monotherapy or UTD1 based therapy 4. Available medical history. Exclusion Criteria: 1.Incomplete medical history.
References
Publications (0)
Data not yet available
No reference posted for this study.